FDA warned Blue Willow Biologics over its NanoBio Protect nasal antiseptic sold with unapproved COVID-19 prevention and treatment claims.
What happened
FDA reviewed the websites bluewillow.com and nanobioprotect.com on March 24, 2021, and found NanoBio Protect Nasal Antiseptic Solution offered for sale with claims that it kills the COVID-19 virus in lab tests, protects for up to 8 hours, and reduces the risk of respiratory infection. FDA noted the product was also for sale on CVS.com. FDA called the product an unapproved new drug and a misbranded drug because of those claims and its nasal use.
What FDA found
The nasal antiseptic is an unapproved new drug because it is not generally recognized as safe and effective for its labeled uses and has no FDA-approved application.
FD&C Act section 505(a), 21 U.S.C. § 355(a)The product is misbranded because its labeling is false or misleading, including the claim that it follows the OTC monograph (FDA’s rulebook for nonprescription drugs) for topical skin antiseptics.
FD&C Act section 502(a), 21 U.S.C. § 352(a)The product is misbranded because it is a nonprescription drug subject to section 505G but does not meet the requirements for marketing under that section and is not covered by an approved application.
FD&C Act section 502(ee), 21 U.S.C. § 352(ee)The label and websites claimed all-day or 8-hour protection against infection and serious-disease pathogens, including COVID-19, going beyond the allowed OTC antiseptic monograph.
FD&C Act section 505G(a)(3), 21 U.S.C. § 355h(a)(3); 1994 TFM as amended by 2016 Consumer Antiseptic Rubs Proposed RuleThe product is intended for use inside and around the nostrils, which is not permitted for consumer antiseptic products under the OTC monograph.
1994 TFM as amended by 2016 Consumer Antiseptic Rubs Proposed RuleThe product was introduced into interstate commerce while unapproved and misbranded.
FD&C Act sections 301(a) and (d), 21 U.S.C. §§ 331(a) and (d)
What FDA wants
FDA tells Blue Willow to take immediate action to correct the violations and, within 48 hours, email COVID-19-Task-Force-CDER@fda.hhs.gov with the specific steps taken to prevent recurrence. If it cannot complete corrections in 48 hours, it must explain the delay and give a completion time.
Who should pay attention
- marketers of OTC antiseptic or nasal products
- retailers and websites selling consumer antiseptics
- companies making COVID-19-related claims for drug products
This is a summary. Read the original letter on fda.gov.